# Regeneron Pharmaceuticals, Inc. (REGN) — Q3-2018 Earnings Results

**Report date:** 2018-11-06 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q3-2018

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 0.76%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $5.87 | N/A | +9.86% |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management expressed confidence in the company's growth trajectory. They noted the importance of innovation and product pipeline.

**Key quotes:**

> Management highlighted strong performance in key product areas.

> They emphasized ongoing investment in research and development.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron's strong EPS performance indicates effective cost management and possibly robust sales in their product lines. The stock's modest increase of 0.76% reflects investor confidence in the company's current trajectory despite the lack of revenue details and guidance. The positive surprise in EPS suggests that the company is performing better than expected in terms of profitability.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q3-2018_